

Figure S1 Overall survival (OS) and progression-free survival (PFS) in patients treated with atezolizumab plus bevacizumab, carboplatin, and paclitaxel as second- or later-line treatment (A,B).




Figure S2 Subgroup analysis of overall survival (OS) (A) and post-progression survival (PPS) (B) in patients treated with atezolizumab plus bevacizumab, carboplatin, and paclitaxel, stratified by post-progression treatment.